Remove Article Remove Licensing Remove Testimonials
article thumbnail

Article FDA Thank You New FDA guidance on addressing misinformation under White House review

Agency IQ

The new draft document comes as FDA leadership has been flagging concerns about misinformation, including in public testimony and reports. Notably, the FDA’s authority over advertising for medical devices is focused on “restricted” medical devices (i.e.,

FDA 40
article thumbnail

Analysis Life Sciences Thank You The 51 regulations that FDA is currently working on

Agency IQ

to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. To implement that authority, FDA published a final rule in the Federal Register on September 15, 2015 [80 FR 55237] which revised 21 CFR 1.94

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in July 2023

Agency IQ

to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. To implement that authority, FDA published a final rule in the Federal Register on September 15, 2015 [80 FR 55237] which revised 21 CFR 1.94

FDA 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in October 2023

Agency IQ

to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. The following PDUFA dates were obtained from publicly available sources. The final rule will amend the administrative destruction provisions in 21 CFR 1.94 to include devices.

FDA 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in November 2023

Agency IQ

and Annex 1 Conference Joel Welch December 18 RAPS RAPS Webcast: FDA Forecast: What’s Next for the FDA in 2024 AgencyIQ Speakers December 21 HL7 REMS Public Call PDUFA Dates expected in November and December PDUFA dates represent the expected date of a regulatory decision by the FDA on a New Drug Application or Biologics License Application.

FDA 40
article thumbnail

PentagonFit Fitness Tracker

The Pharma Data

In the process, I’ve reviewed thousands of research articles, played a key role in publishing real clinical studies and as a surgeon, operated on hundreds of patients often in life-or-death scenarios. LEGAL DISCLAIMER: All testimonials in this advertisement are from real people. Just Pay Shipping. Limited Supplies Avaiable.

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in December 2023

Agency IQ

to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. The following PDUFA dates were obtained from publicly available sources. The final rule will amend the administrative destruction provisions in 21 CFR 1.94 to include devices.

FDA 40